Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Share-based Compensation (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Share-based Compensation for 6 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 15.21% year-over-year to $1.1 million, compared with a TTM value of $4.9 million through Sep 2025, down 28.41%, and an annual FY2024 reading of $6.3 million, down 13.85% over the prior year.
  • Share-based Compensation was $1.1 million for Q3 2025 at Ovid Therapeutics, down from $1.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.0 million in Q1 2024 and bottomed at $1.1 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $1.5 million, with a median of $1.3 million recorded in 2022.
  • The sharpest move saw Share-based Compensation tumbled 55.59% in 2021, then surged 53.37% in 2022.
  • Year by year, Share-based Compensation stood at $1.3 million in 2021, then surged by 31.51% to $1.7 million in 2022, then rose by 3.43% to $1.8 million in 2023, then decreased by 29.57% to $1.3 million in 2024, then decreased by 11.98% to $1.1 million in 2025.
  • Business Quant data shows Share-based Compensation for OVID at $1.1 million in Q3 2025, $1.2 million in Q2 2025, and $1.3 million in Q1 2025.